Johnson & Johnson (JNJ)
Johnson & Johnson units to pay $65 million to settle Tracleer antitrust class action
Two Johnson & Johnson units have agreed to pay $65 million to settle a proposed antitrust class action by health plans and others claiming they were overcharged for the pulmonary hypertension drug Tracleer.
Johnson & Johnson launches website for direct-to-consumer sales
Johnson & Johnson has launched a website to sell some of its drugs directly to U.S. patients who either don't have insurance or pay for their drugs out of pocket.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Johnson & Johnson (JNJ) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Immunology, Neuroscience Step Up as Key Growth Engines for J&J
JNJ's immunology and neuroscience units are driving growth, with Tremfya, Caplyta and Spravato offsetting Stelara's LOE hit.
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
Johnson & Johnson (JNJ) closed the most recent trading day at $248.43, moving +2.04% from the previous trading session.
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
Johnson & Johnson's JNJ stock has risen 38.4% in the past six months. The stock has also been trading above its 50-day and 200-day simple moving averages (SMAs) for more than eight months since mid-June 2025 due to its positive earnings outlook and improving fundamentals.
Are You Looking for a High-Growth Dividend Stock?
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Can J&J Sustain Its Double-Digit Oncology Growth Streak?
Johnson & Johnson JNJ is one of the key pharmaceutical players in the oncology segment with significant expertise in blood cancers and solid tumors. It is the #1 company in multiple myeloma, with key drug Darzalex being considered the foundational gold standard treatment.
Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
While the technology sector faces a renewed wave of volatility driven by artificial intelligence (AI) scare trades and valuation concerns, a different story is unfolding in the healthcare sector. Investors fleeing the jittery price swings of high-growth tech stocks are finding shelter in a familiar name that is quietly outperforming.
Wall Street Bulls Look Optimistic About Johnson & Johnson (JNJ): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings Report?
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
